文献速递前列腺癌

60岁前基线前列腺特异性抗原值在预测致死性前列腺癌中的作用:一项当代北美队列分析

The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort.
PubMed 文献 · Eur Urol Oncol · 2024-07-10

该研究纳入1995至2019年间在医疗系统内首次接受PSA检测的40-59岁男性129067例,按年龄分组,评估60岁前基线PSA对致死性前列腺癌的预测作用。中位随访7.4年,基线PSA≥90百分位者致死性前列腺癌风险显著高于PSA<中位数者(HR 7.48,95%CI 6.20-9.03),前列腺癌发生风险HR为20.47(95%CI 18.58-22.55)。作者认为基线PSA是调整后续筛查频率的最有效工具。

要点

  • 40-59岁男性基线PSA≥90百分位者致死性前列腺癌风险是PSA<中位数者的7.48倍(HR 7.48,95%CI 6.20-9.03)。
  • 基线PSA≥90百分位者前列腺癌发生风险是PSA<中位数者的20.47倍(HR 20.47,95%CI 18.58-22.55)。
  • 作者认为60岁前基线PSA是调整后续筛查频率的最有效工具。

核心结论

  • 在大型当代北美多样化队列中,基线PSA是后续致死性前列腺癌风险的非常强预测因子,该队列接受了机会性PSA筛查。
  • 该关联远大于多基因风险评分的关联,证实60岁前基线PSA是调整后续筛查的最有效工具。
  • 与未筛查队列研究相比, incident与致死性疾病之间的区分度差异较小,反映了筛查的影响。

研究设计与样本

  • 队列纳入1995至2019年间在医疗系统内首次接受PSA检测的所有40-59岁男性。
  • 按年龄分为40-44、45-49、50-54和55-59岁四组,基线PSA为预测变量。
  • 致死性疾病定义为前列腺癌死亡或诊断时/随访期间发生转移性疾病。
  • 通过链接密歇根生命记录登记处获取癌症特异性死亡和总死亡数据。
  • 采用竞争风险回归评估PSA与致死性前列腺癌的关联。

主要发现

  • 共129067例男性符合纳入标准,无癌患者中位随访7.4年。
  • 40-44、45-49、50-54、55-59岁组中,PSA<中位数者20年致死性前列腺癌估计率分别为0.02%、0.14%、0.33%、0.51%,PSA≥90百分位者分别为0.79%、0.16%、2.5%、5.4%。
  • 同年龄组中,PSA<中位数者20年任何前列腺癌估计率分别为1.6%、2.9%、3.9%、5.8%,PSA≥90百分位者分别为25%、28%、38%、39%。
  • 多变量分析中,与PSA<中位数者相比,PSA≥90百分位者致死性疾病风险比HR为7.48(95%CI 6.20-9.03)。
  • 多变量分析中,与首次PSA<中位数者相比,PSA≥90百分位者前列腺癌发生风险比HR为20.47(95%CI 18.58-22.55)。

临床怎么用

  • 作者认为初次PSA水平可用于调整后续PSA检测的频率。
  • 作者认为60岁前基线PSA是调整后续筛查的最有效工具。

局限性

  • 局限性包括中位随访时间较既往文献更短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Studies evaluating the role of baseline midlife prostate-specific antigen (PSA) as a predictor of development and progression of prostate cancer relied predominately on cohorts from the pre-PSA screening introduction era. The aim of our study was to examine the role of baseline PSA prior to the age of 60 yr as a predictor of developing lethal prostate cancer using a contemporary North American cohort. METHODS: Our cohort included all men aged 40-59 yr who received their first PSA through our health system between the years 1995 and 2019. Patients were divided into four categories based on age: 40-44, 45-49, 50-54, and 55-59 yr. Baseline PSA was the predictor of interest. Lethal disease was defined as death from prostate cancer or development of metastatic disease either at diagnosis or during follow-up. Cancer-specific mortality and overall mortality were obtained by linking our database to the Michigan Vital Records registry. Competing-risk regression was used to evaluate the association between PSA and lethal prostate cancer. KEY FINDINGS AND LIMITATIONS: A total of 129067 men met the inclusion criteria during the study period. The median follow-up for patients free from cancer was 7.4 yr. For men aged 40-44, 45-49, 50-54, and 55-59 yr, the estimated rates of lethal prostate cancer at 20 yr were 0.02%, 0.14%, 0.33%, and 0.51% in men with PSA <median, and 0.79%, 0.16%, 2.5%, and 5.4% in men with PSA ≥90th percentile, respectively. For the same age category, the estimated rates of any prostate cancer at 20 yr were, respectively, 1.6%, 2.9%, 3.9%, and 5.8% in men with PSA <median, and 25%, 28%, 38%, and 39% in men with PSA ≥90th percentile. On a multivariable analysis, men with PSA ≥90th percentile had a hazard ratio of 7.48 (95% confidence interval [CI]: 6.20-9.03) for lethal disease, when compared with those with PSA <median. On the multivariable analysis, men with PSA ≥90th percentile had a hazard ratio of 20.47-fold (95% CI: 18.58-22.55) for prostate cancer incidence, when compared with those with PSA <median at first. Limitations included shorter median follow-up than prior literature. CONCLUSIONS AND CLINICAL IMPLICATIONS: Baseline PSA is a very strong predictor of the subsequent risk of developing lethal prostate cancer in a large contemporary diverse North American cohort, which was exposed to opportunistic PSA screening. The association was far larger than that found for polygenic risk scores, confirming that baseline PSA prior to the age of 60 yr is the most effective tool for adjusting subsequent screening. Compared with studies of unscreened cohorts, there was a smaller difference in discrimination between incident and lethal disease, reflecting the influence of screening. PATIENT SUMMARY: In this study, we found that a single baseline prostate-specific antigen (PSA) value is strongly predictive of the subsequent risk of developing metastatic prostate cancer, as well as the risk of dying from prostate cancer. The initial PSA level can therefore be used to adjust the frequency of subsequent PSA testing.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Finati M, Davis M, Stephens A, et al. The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort. Eur Urol Oncol. 2024. PMID: 38991891. doi:10.1016/j.euo.2024.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。